ReviewJournal of translational medicine2014
The triggering receptor expressed on myeloid cells (TREM) in inflammatory bowel disease pathogenesis.
Review in Journal of translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 59 citations in OpenAlex.
- TREM-1-dependent macrophage infiltration mediates visceral hypersensitivity via vlPAG GABAergic neuron activation in a mouse model of inflammatory bowel disease.Cellular & molecular biology letters · 2026Article
- Evidence of an allostatic response by intestinal tissues following induction of joint inflammation.PloS one · 2026Article
- Molecular links between inflammatory bowel disease and Alzheimer's disease through immune signaling and inflammatory pathways.World journal of gastroenterology · 2025Review
- Bullous Pemphigoid Develops Independently of DAP12.Biomolecules · 2025Article
- Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumab.Research square · 2025Article
- TREM-1 as a potential gatekeeper of neuroinflammatory responses: therapeutic validation and mechanistic insights in experimental traumatic brain injury.Frontiers in immunology · 2025Article
- TREM2Frontiers in immunology · 2025Review
- Expressional and prognostic value of TREM1 in ovarian cancer: A comprehensive study based on bioinformatics and clinical analysis validation.Journal of Cancer · 2025Article
- Single-Cell and Spatial Multi-omics Reveal Interferon Signaling in the Pathogenesis of Perianal Fistulizing Crohn's Disease.bioRxiv : the preprint server for biology · 2024Article
- Microglia TREM1-mediated neuroinflammation contributes to central sensitization via the NF-κB pathway in a chronic migraine model.The journal of headache and pain · 2024Article
- TREM-1 and TREM-2 as therapeutic targets: clinical challenges and perspectives.Frontiers in immunology · 2024Article
- Natural Drugs: A New Direction for the Prevention and Treatment of Diabetes.Molecules (Basel, Switzerland) · 2023Review
- Role of CD34 in inflammatory bowel disease.Frontiers in physiology · 2023Review
- Inhibition of TREM-2 Markedly Suppresses Joint Inflammation and Damage in Experimental Arthritis.International journal of molecular sciences · 2022Article
- Serum Levels of Soluble Triggering Receptor Expressed on Myeloid Cells-1 Associated with the Severity and Outcome of Acute Ischemic Stroke.Journal of clinical medicine · 2020Article
- Hypoxia Augments Cerebral Inflammation in a Dextran Sulfate Sodium-Induced Colitis Mouse Model.Frontiers in cellular neuroscience · 2020Article
- Review
- TREM-1 regulates neutrophil chemotaxis by promoting NOX-dependent superoxide production.Journal of leukocyte biology · 2019Article
- Clinical significance of soluble immunoglobulins A and G and their coated bacteria in feces of patients with inflammatory bowel disease.Journal of translational medicine · 2018Article
- The Characterization of Monoclonal Antibodies to Mouse TLT-1 Suggests That TLT-1 Plays a Role in Wound Healing.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Triggering Receptors Expressed on Myeloid cells (TREM) are a family of cell-surface molecules that control inflammation, bone homeostasis, neurological development and blood coagulation. TREM-1 and TREM-2, the best-characterized receptors so far, play divergent roles in several infectious diseases. In the intestine, TREM-1 is highly expressed by macrophages, contributing to inflammatory bowel disease (IBD) pathogenesis. Contrary to current understanding, TREM-2 also promotes inflammation in IBD by fueling dendritic cell functions. This review will focus specifically on recent insights into the role of TREM proteins in IBD development, and discuss opportunities for novel treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.